High Systemic Immune-Inflammation Index (SII) Represents an Unfavorable Prognostic Factor for Small Cell Lung Cancer Treated with Etoposide and Platinum-Based Chemotherapy.

Chunyan WangShi JinShanqi XuShoubo Cao

Published in: Lung (2020)

Pretreatment SII represents a powerful prognostic biomarker for SCLC patients treated with etoposide and platinum-based chemotherapy. It is significant for treatment strategy making in clinics.

Keyphrases

prognostic factors
small cell lung cancer
locally advanced
oxidative stress
primary care
radiation therapy
smoking cessation